Showing results (11-20 of 44) with videos related to
Sort By:
Pageof 5
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 29, 2019
Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantationFrancisco M Marty, Per T Ljungman, Roy F Chemaly, et al.European Journal of Clinical Pharmacology|January 26, 2019
Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairmentLuzelena Caro, Larissa Wenning, Hwa-Ping Feng, et al.Antimicrobial Agents and Chemotherapy|February 20, 2024
A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illnessDavid Plotnik, Jennifer E Sager, Madhukar Aryal, et al.Journal of Virology|April 26, 2012
Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeysWendy W Yeh, Laura M Brassard, Caroline A Miller, et al.Clinical Pharmacology in Drug Development|June 8, 2019
Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult ParticipantsHwa-Ping Feng, Zifang Guo, Christine Fandozzi, et al.European Journal of Clinical Pharmacology|February 25, 2017
No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrelWilliam L Marshall, Hwa-Ping Feng, Luzelena Caro, et al.Journal of Virology|February 11, 2011
Epitope-specific CD8+ T lymphocytes cross-recognize mutant simian immunodeficiency virus (SIV) sequences but fail to contain very early evolution and eventual fixation of epitope escape mutations during SIV infectionEvan M Cale, Peter Hraber, Elena E Giorgi, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2024
A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)Susanna K Tan, Deborah Cebrik, David Plotnik, et al.Clinical Drug Investigation|February 2, 2021
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy AdultsLuzelena Caro, Thomayant Prueksaritanont, Christine M Fandozzi, et al.Antimicrobial Agents and Chemotherapy|August 26, 2015
Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvirRong Liu, Stephanie Curry, Patricia McMonagle, et al.Pageof 5